Vet’s Hub Article Volume 1| January 2026
When prescriptions fail, V-Tech fills the gap
For most veterinarians, the treatment plan on paper and the medicines actually available on the shelf do not always match.
You know the list: Chronic patients that need a non-standard dose, cats that refuse the only formulation on the market; rabbits, reptiles and birds with no labelled options, wildlife and production animals where a ‘human generic’ is not good enough – or where the product you’ve relied on for years is suddenly discontinued or out of stock. That gap between what a case needs and what the market supplies is the space V-Tech has deliberately stepped into.
Established in 2003 in Midrand by veterinarians Drs Johan Oosthuyse and David Gerber, V-Tech was born out of a simple, uncomfortable truth: There was a ‘desperate call’ from vets for reliable compounded medicines that could be tailored to real-world clinical needs. What started as a conservation-focused community pharmacy has grown into the largest veterinary compounding pharmacy in South Africa, serving companion animals (including exotics), poultry, livestock and wildlife across South and Southern Africa from a 2500m², two-pharmacy facility and contract manufacturing plant in Midrand, South Africa. For many clinicians today, V-Tech is not a ‘nice-to-have extra’, but part of their standard therapeutic toolbox.
Custom meds for every patient.
At its core, V-Tech’s business is veterinary compounding: Creating customised medications in specific strengths, combinations and dosage forms when off-the-shelf options are unsuitable, unavailable or simply do not exist. That may mean converting a tablet into an accurately dosed, flavoured liquid for a toy-breed dog, producing a small, easy-to-hide capsule for a cat that has to stay on long-term therapy, or reformulating to remove excipients that a particular patient cannot tolerate. In other cases, it involves building completely new formulations for species and conditions that have never had a labelled medicine, especially within wildlife and exotic practice. V-Tech’s compounding capability is deliberately broad. Between the V-Tech Prescriptions Pharmacy and the V-Tech Veterinary Solutions Pharmacy, the business produces an array of dosage forms: Large-volume dry powders and liquids, creams, gels, lotions and shampoos, tablets, capsules and pastes, as well as small-volume sterile injectables. For the vet in practice, this means a single partner can help solve day-to-day compliance problems in small animals, design medicated feed or water treatments for intensive systems, and support highly specialised protocols in exotic pets or wildlife.
Tailored meds beyond the ordinary
Wildlife and exotic work remain one of V-Tech’s signature strengths. Traditional veterinary medicines are often inappropriate or unavailable for the diversity of species seen in parks, private game reserves, zoos, aquariums and specialist practices. From its early days, the company’s pharmacists and wildlife veterinarians have worked with field specialists to develop and refine medicines for sedation, translocation, immobilisation, ongoing treatment and supportive care in wild species, as well as a dedicated exotics range for birds, small mammals, reptiles and fish.
These formulations are tested in real conditions through a network of specialist vets and conservation programmes, with feedback loops that feed directly into formulation improvement and dosing guidance.
Keeping patients on track when medicines vanish
Another part of V-Tech’s role is ensuring continuity when commercial products disappear. Using its compounding capacity, the company can step in when critical medicines are discontinued or temporarily out of stock, maintaining therapy so that chronic and high-risk patients are not destabilised merely because a manufacturer has changed strategy or a shipment has been delayed. In a market where supply disruptions are becoming more common, that ‘bridge’ function is increasingly important to day- to-day practice.
Quality and compliance you can trust
Behind the visible products is a business model that looks and behaves much more like a pharmaceutical manufacturer than a traditional pharmacy. V-Tech’s South African site operates under ISO 9001:2015 and ISO 13485:2016 certification, issued by international bodies, signalling rigorous quality management and medical-device standards. Both pharmacies hold Grade A community pharmacy licences with the South African Pharmacy Council and are registered as training facilities. The company is licensed by the National Department of Health to compound veterinary medicines, by the Department of Agriculture to manufacture and export stock remedies, and by SAHPRA to distribute certain medical devices. That regulatory backbone is supported by detailed internal systems. Quality assurance at V-Tech spans supplier selection and auditing, the use of active pharmaceutical ingredients that comply with the relevant British Pharmacopoeia, United States Pharmacopoeia and/or European Pharmacopoeia standards, batch documentation and traceability, external laboratory testing where required, and structured non-conformance and Corrective and Preventive Action processes. Risk assessments, data analysis and regular internal and external audits guide decisions on everything from process changes to facility upgrades. For veterinarians, the result is confidence that a compounded medicine is not an informal ‘mix up’, but the output of a controlled, documented and auditable system.
Partnering on antimicrobials and One Health
Beyond individual prescriptions, V-Tech has also positioned itself as a technical partner to intensive livestock systems through its antimicrobial resistance (AMR) surveillance and monitoring programmes. The company’s laboratory produces specialised minimum inhibitory concentration (MIC) plates containing panels of antimicrobials. Pathological bacteria, such as Escherichia coli isolates from post-mortem samples or trans-tracheal washes, are tested against these plates to determine the most appropriate drug and dosing regimen for a specific unit. In parallel, a monitoring programme checks that compounded antibiotics added to feed or water are present at the intended concentration and that, at slaughter, tissue samples comply with residue limits for meat destined for human consumption. For vets working in poultry, beef or pork production, this means the pharmacy is not only supplying medicines, but also supporting evidence-based, responsible antimicrobial use. It also underscores V-Tech’s broader positioning within a One Health frame: Animal health solutions that are compatible with human food safety and long-term stewardship goals.
Precision manufacturing beyond the pharmacy
Another important strand of the business is specialised contract manufacturing. Drawing on its facilities and staff, V-Tech manufactures feed supplements, oral powders, topical preparations, liquids, gels and lotions on behalf of veterinary pharmaceutical companies in South Africa and other SADC countries, under the requirements of Act 36 of 1947. These products are manufactured to the same quality standards that apply to V-Tech’s own compounded medicines. In addition, the company distributes selected veterinary medical devices for the region under Act 101 of 1965, including technologies such as regenerative and joint therapies from international partners.
Building skills and confidence in veterinary compounding
Internally, V-Tech invests in skills and professional development through the V-Tech Training Academy, which runs programmes for both internal staff and external participants. Training spans technical compounding, quality systems, AMR, and the regulatory context of compounded medicines. For younger vets and practice teams, these sessions help demystify compounding, clarify where it fits within South African law, and highlight both its power and its limits as a therapeutic tool.
Partnering on solutions when standard is not enough
The focus on the regulatory environment is not merely academic. V-Tech has taken an active role in discussions around how veterinary compounding is governed, contributing to industry and professional forums and, where necessary, turning to litigation to defend veterinarians’ ability to prescribe and use compounded medicines when they are clinically indicated.
In a landscape where regulation, enforcement and professional responsibility are under increasing scrutiny, this advocacy positions the company as more than a supplier: It is a stakeholder in the future of the profession’s therapeutic freedom. Philosophically, V-Tech remains distinctly veterinary-led. The company grew out of nature conservation work where the patients were high-value wild animals and the margin for error was very small. The origin story still informs the way the business approaches problem-solving: Start with the animal and the case, consider the practicalities of the field or the production system, then design the pharmacy solution.
On any given day, that might involve working with a small-animal clinician to design a more practical regimen for a fractious cat, helping a wildlife vet refine a darting or translocation protocol, or partnering with a poultry veterinarian to re-evaluate an antimicrobial programme in response to new MIC data. For veterinarians, the value of a partner like V-Tech is not just the list of products in a catalogue. It is the combination of clinical understanding, formulation science, manufacturing capacity, quality systems and regulatory insight that sits behind each bottle, blister, vial or sachet. It is having a team that can say ‘yes, that is possible’ when a case does not fit the standard template or ‘no, that is not justified’ when the risk–benefit balance is not in the animal’s favour. As pressures on the profession increase – from economic constraints and supply-chain volatility to AMR concerns and shifting regulations – the ability to individualise therapy safely will only become more important.
V-Tech’s trajectory over the past two decades suggests one model for how a veterinary compounding business can support that: Deeply embedded in the profession, technically robust, and willing to innovate while remaining grounded in quality and compliance. For those long nights when you are still thinking about a complex case or a fragile production system, that does not remove the weight of clinical responsibility. But it does mean that when the perfect product isn’t on the shelf, there is a specialist pharmacy in Midrand whose core business is to help you build the next best option for the animal in front of you.
Thank you to Vet’s Hub for featuring V-Tech in your very first volume.
View the full issue here: https://issuu.com/newmediab2b/docs/vet_s_hub_volume_1_number_1